Treatment strategies in mild asthma

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 1, 2009, Pages 29-34

  Papi, Alberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

As needed inhaled corticosteroids; Asthma control; Mild intermittent asthma; Mild persistent asthma

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE; BECLOMETHAZONE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; PLACEBO; PREDNISONE; SALBUTAMOL; TERBUTALINE; UNCLASSIFIED DRUG; ZAFIRLUKAST;

BRONCHODILATATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; EARLY INTERVENTION; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MAINTENANCE THERAPY; MILD INTERMITTENT ASTHMA; MILD PERSISTENT ASTHMA; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; REVIEW; TREATMENT OUTCOME; WHEEZING;

EID: 58149269176     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32831da8fd     Document Type: Review

References (43)

1. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007; 62:591-604. The French viewpoint: un update state of the art on mild asthma reviewed by a group of French experts.
2. Kwok MY, Walsh-Kelly CM, Gorelick MH, et al. National Asthma Education and Prevention Program severity classification as a measure of disease burden in children with acute asthma. Pediatrics 2006; 117:S71-S77.
3. National Asthma Educational and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 97-4051. 1997.
4. Lazarus SC. Mild persistent asthma: is any treatment needed? J Allergy Clin Immunol 2006; 118:805-808.
5. Martinez FD. Asthma treatment and asthma prevention: a tale of 2 parallel pathways. J Allergy Clin Immunol 2007; 119:30-33.
6. Ward C, Walters H. Airway wall remodelling: the influence of corticosteroids. Curr Opin Allergy Clin Immunol 2005; 5:43-48.
7. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6:13.
8. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113:245-251.
9. Home R, Price D, Cleland J, et al. Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 2007; 7:8.
10. O'Byme PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397.
11. Pauwels RA, Busse WW, O'Byrne PM, et al. The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. Control Clin Trials 2001; 22:405-419.
12. Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167-1174.
13. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-1063.
14. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997.
15. Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998-2005.
16. Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754-762.
17. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519-1528.
18. van den Toorn LM, Overbeek SE, de Jongste C, et al. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001; 164:2107-2113.
19. Polosa R, Ciamarra I, Mangano G, et al. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J 2000; 15:30-35.
20. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368:744-753.
21. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007; 29:587-595.
22. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160:594-599.
23. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040-2052. This is the first study evaluating the efficacy of as-needed ICS, in combination with a short-acting bronchodilator, in patients with mild persistent asthma and no maintenance therapy.
24. Ni CM, Greenstone IR, and Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev 2005: CD005307.
25. Peters SP, Anthonisen N, Castro M, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma N Engl J Med 2007; 356:2027-2039. This study compares three different regimen options in mild persistent asthma, that is, b.i.d. (twice daily) low-dose ICS or qd ICS/LABA combination or regular antileukotriene treatment, using time to treatment failure as primary outcome.
26. Martinez FD. Serious adverse events and death associated with treatment using long-acting beta-agonists. Clin Rev Allergy Immunol 2006; 31:269-278.
27. Peters-Golden M. Expanding roles for ieukotrienes in airway inflammation. Curr Allergy Asthma Rep 2008; 8:367-373.
28. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315-322.
29. Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120:e702-e712. This trial documents the clinical efficacy of antileukotrienes in preventing virusassociated asthma exacerbations in children.
30. Ng D, Salvio F, Hicks G. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004: CD002314.
31. Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 2001; 95:379-386.
32. Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol 2005; 115:47-54.
33. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
34. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45-52.
35. Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007; 119:64-72.
36. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-178.
37. National Asthma Educational and Prevention Program, National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 07-4051. 2007.
38. O'Byme PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 2006; 368:794-803.
39. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841-847.
40. Israel E, Drazen JM. Treating mild asthma: when are inhaled steroids indicated? N Engl J Med 1994; 331:737-739.
41. Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006; 28:748-755.
42. Drazen JM, Campion EW, Curfman GD, et al. Clinical decisions. N Engl J Med 2007; 356:2093. A fictitious case of mild persistent asthma is described and different treatment options are proposed. Three experts make a case in support of one of the proposed options.
43. Fredenburgh LE, Campion EW, Drazen JM. Clinical decisions. Mild persistent asthma: polling results. N Engl J Med 2007; 357:179-180. The results of an open web forum on different options for the treatment of mild persistent asthma are reported and discussed.